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Abstract
Terbium (Tb3) has been shown to increase the cellular accumulation and cytotoxicity of cisplatin in cisplatin-resistant
human breast and ovarian cancer cells. Time-resolved Tb3 luminescence was used to describe the binding of cisplatin to
cisplatin-resistant C13* cells. A high-affinity Tb3 binding site was identified in the plasma membrane of the C13* cells
(n = 105 þ 2 fmol/cell and Kd = 36.3 þ 5.2 WM). The binding of Tb3 is suggested to occur through a cation^Z interaction with
tryptophan residues in the plasma membrane, resulting in an enhancement of the intensity and lifetime of Tb3. Stern^
Volmer quenching analysis revealed that the Tb3 binding site is not readily accessible to the aqueous environment. The
quenching of the Tb3^C13* intensity by cisplatin occurred by static quenching processes, involving both a direct electron-
exchange interaction as well as an indirect dipole^dipole resonant energy transfer mechanism. Formation of the Tb3^C13*^
cisplatin complex does not interfere with the high-affinity binding of Tb3 ; cisplatin and Tb3 bind within 5 to 10 Aî of each
other. A specific terbium/cisplatin binding protein is suggested to play a role in the cellular accumulation and cytotoxicity of
cisplatin. Therefore, the transport of cisplatin across the plasma membrane must also involve a facilitated diffusion process.
Our results indicate that the binding of Tb3 to the plasma membrane may be potentially useful in the reversal of cisplatin
resistance. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cisplatin is a broad-spectrum chemotherapeutic
agent and is very e¡ective in the treatment of ovarian
and testicular cancer [1,2]. Unfortunately, the de-
velopment of cellular resistance to cisplatin has
hampered the clinical use of the drug. Resistance
to cisplatin is characterized by reduced cellular
accumulation of the drug, increased inactivation of
the drug, and/or enhanced repair of damaged DNA.
Various strategies have been developed to address
the speci¢c features of cisplatin resistance [3]. Since
cisplatin accumulation is a major determinant of its
antitumor activity, research into the mechanism of
transport of cisplatin across the plasma membrane
is warranted. The cytotoxic activity of cisplatin has
been shown to be proportional to the amount of
cisplatin accumulated in the cell [4]. Many modula-
tors of the cellular accumulation of cisplatin have
been investigated, and because of their relatively
low toxicities, calcium channel blockers are ideal
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agents to be used in cisplatin combination chemo-
therapy [1].
Nifedipine, a dihydropyridine calcium channel
blocker, has been found to synergistically enhance
the cytotoxicity of cisplatin in murine metastatic
B16 amelanotic melanoma cancer cells [5,6]. Verapa-
mil, a structurally di¡erent calcium channel blocker
of the phenylalkylamine class, and diltiazem, of the
benzothiazepine class, were not able to increase the
cytotoxicity of cisplatin. This implies that the ability
of a calcium channel blocker to increase the cyto-
toxic action of cisplatin varies among the di¡erent
classes of such blockers. Cisplatin has also been
shown to induce apoptosis in both human and mur-
ine ovarian cancer cells, as well as in human multi-
drug-resistant glioblastoma cells [7^10]. At relatively
low cisplatin concentrations, the combination of cis-
platin and nifedipine was found to synergistically
enhance apoptosis induced by cisplatin [10]. The
modulation of cisplatin cytotoxicity and cisplatin-in-
duced apoptosis by nifedipine was suggested to be
due to its interaction with an uncharacterized ‘target
site’ in the plasma membrane, which is independent
of the inhibitory e¡ect of nifedipine on the Ca2
channel [6,10].
In 1986, a leap of faith was made; a speci¢c
terbium/cisplatin binding protein was postulated to
play a signi¢cant role in the transport of cisplatin
across the plasma membrane [11]. The mechanism
by which cisplatin is transported across the plasma
membrane is not known. Recently, Tb3 has been
discovered to increase the cellular accumulation
and/or cytotoxicity of cisplatin in human breast
and ovarian cancer cells, as well as human head
and neck cancer cells [12^16]. Tb3 is a rare earth,
lanthanide metal and an inorganic calcium channel
blocker [17]. It has been utilized as a luminescent
probe of Ca2 binding sites in isolated protein, mem-
brane, and cellular systems [18^22]. Tb3 does not
enter intact living cells but binds to their outer mem-
brane surface [20]. The binding of Tb3 to the plas-
ma membrane has been suggested to modulate the
cellular activity of cisplatin in human ovarian cancer
cells [15,16]. The putative terbium/cisplatin binding
protein must be isolated and puri¢ed before any de-
¢nitive statement can be made about its role in cis-
platin transport. However, increasing evidence sug-
gest that the initial transport of cisplatin involves
passive as well as carrier-mediated di¡usion proc-
esses [23]. The objective of this report is to describe
the binding of Tb3 and cisplatin to cisplatin-resist-
ant C13* human ovarian cancer cells.
2. Materials and methods
2.1. Chemicals
Cis-dichlorodiammineplatinum(II) (cisplatin) and
terbium(III) trichloride hexahydrate (TbCl3W6H2O)
were purchased from Aldrich Chemical Co. (Milwau-
kee, WI). Tb3 stock solutions were made with high-
quality water, 18 M6-cm. The water was processed
by reverse osmosis and deionization. Cisplatin stock
solutions were made fresh 24 h. before each experi-
ment in Hepes-bu¡ered saline (HBS). This procedure
minimized the hydrolyzation of cisplatin into the
aquo species. The bu¡er solution was made without
phosphate or carbonate ions to prevent the forma-
tion of Tb3^PO4 or Tb3^CO3 complexes. HBS
contained 145 mM NaCl, 5 mM KCl, 1 mM
MgCl2W6H2O, 1 mM CaCl2W6H2O and 6 mM D-glu-
cose in 10 mM Hepes (pH 7.2). The pH of HBS was
adjusted to 7.2 to reduce the precipitation of terbium
hydroxide. All chemicals were of high analytical
quality and were used as received.
2.2. Cell culture
The cisplatin-resistant C13* subline was generated
from 2008 human ovarian cancer cells by monthly
selection with 1 WM cisplatin, as previously described
[24]. The parent cisplatin-sensitive 2008 cell line was
established from a patient with serous cystadenocar-
cinoma of the ovary. The cells were grown in RPMI-
1640 medium supplemented with 10% heat-inacti-
vated fetal bovine serum without antibiotics. They
were maintained as a monolayer in 75-cm2 vented
culture £asks at 37‡C in a humidi¢ed atmosphere
of 5% CO2 and 95% air.
2.3. Luminescence measurements
Con£uent cell cultures were harvested with tryp-
sin^EDTA (0.5 g porcine trypsin in 0.2 g EDTAW4
Na/liter Hank’s balanced salt solution) and washed
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twice by centrifugation with HBS. Cells were counted
using a hemacytometer, and viability (80 þ 5%) as-
sessed by trypan blue exclusion. The ¢nal pooled
pellet was resuspended in HBS, and placed on ice
until use. Time-resolved luminescence spectra and
intensities were measured on a Spex Industries Fluo-
rolog-2 Model F212I spectro£uorometer, equipped
with a phosphorimeter accessory. The cell suspen-
sions were excited with a pulsed xenon lamp (7 W),
having a pulse width at 1/3 peak intensity of less than
15 Ws. The excitation wavelength and entrance slit
were set at 280 and 5 nm, respectively. The emission
wavelength and exit slit were set at 543 and 10 nm,
respectively. A 450-nm long-wave pass ¢lter was
placed between the exit slit and emission monochro-
mator. Each data point was the accumulation of 100
£ashes at a pulse rate of 10/s. The duration of the
sample window was set at 100 Ws. Gating of the
sample photomultiplier was delayed by 50 Ws after
the £ash of the xenon lamp, to eliminate any errors
due to light scattering and interferences due to the
intrinsic £uorescence of the cells (for the C13* £uo-
rescence measurements, the gating of the sample
photomultiplier was synchronized with the £ash of
the xenon lamp). All measurements were made on
3-ml samples in 1U1-cm quartz cuvettes at 37‡C
while under gentle stirring. A ‘blank’ titration was
performed in HBS without cells. The intensity of
the Tb3^C13* complex (vI) was calculated at each
Tb3 concentration; vI is equal to the intensity of
Tb3 in the presence of cells minus the intensity of
Tb3 in the absence of cells. The details of each ex-
periment are outlined in the ¢gure legends.
The luminescence intensity of free Tb3 has been
shown to increase linearly as a function of the Tb3
concentration in dipicolinic acid [25]. The stoichiom-
etry of Tb3 binding, i.e., the number of Tb3 bind-
ing sites per cell, was determined by subtracting the
concentration of free Tb3 in solution, from the total
amount of Tb3 incubated with the cells, and divid-
ing the di¡erence by the cell concentration. Tb3, at
100 WM, was interacted with 5U105 cells/ml for 60
min at 37‡C in HBS, with or without 1.0 mM cispla-
tin. Due to a large population of cells (and therefore,
a large number of binding sites), a high cisplatin
concentration was employed to saturate all of the
binding sites. The reaction was stopped and the cells
removed from the suspensions via ultra¢ltration
through a 0.22 Wm syringe ¢lter. Tb3 standards (0,
25, 50, 75, 100 and 125 WM) in HBS were also ¢l-
tered. (Tb3 does not bind to the cellulose acetate
membranes of the ¢lters.) Afterwards, 100-Wl ali-
quots of the ¢ltrates and standards were interacted
with 2.9 ml of 0.5 mM dipicolinic acid in 154 mM
NaCl and 10 mM Hepes, pH 7.2. The intensities of
the Tb3^dipicolinic acid complex were measured
with a Perkin^Elmer LS-5B spectro£uorometer in
1U1-cm quartz cuvettes at room temperature. A
standard curve was generated with the Tb3 stand-
ards. Linear regression analysis was used to deter-
mine the concentration of free Tb3 in the ¢ltrates.
The samples were excited by a pulsed xenon lamp
(9.9 W) having a pulse width at 1/2-peak intensity
of less than 10 Ws. The excitation wavelength and
entrance slit were set at 280 and 5 nm, respectively;
the emission wavelength and exit slit were set at 543
and 10 nm, respectively. The gating of the sample
photomultiplier was delayed by 100 Ws after the £ash
of the xenon lamp. The sample window was set at a
0.10 ms duration. In addition, a long-wave pass ¢lter
of 399 nm was employed to reduce interference due
to light scatter from the excitation beam.
2.4. Theoretical considerations
Electronic excitation energy may be nonradiatively
transferred through-space via a Fo«rster-type dipole^
dipole mechanism [26]. The e⁄ciency of energy
transfer (E) is related to the actual distance of sepa-
ration (r) between the excited donor and the station-
ary acceptor, in that:
r  Ro13EE 
1=6 1
where Ro is the ‘critical Fo«rster distance’ over which
the e⁄ciency of energy transfer is 50%. Ro (in Aî ) can
be calculated from spectroscopic and geometric var-
iables by the equation:
Ro  9:79U103JR34K2Qo1=6 2
J is the spectral overlap integral (in cm3 M31), R is
the refractive index of the intervening medium, K2 is
the orientation factor for the donor and acceptor
transition dipole moments, and Qo is the absolute
quantum yield of the energy donor in the absence
of acceptor. The spectral overlap integral is directly
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calculated from the emission spectrum of the donor
(normalized to unity) and the absorption spectrum of
the acceptor, according to the relationship:
J 
R
FV OV V4 dVR
FV dV 3
F(V) is the relative £uorescence intensity of the
donor as a function of wavelength V, and O(V) is
the molar absorptivity (in M31 cm31) of the acceptor
at wavelength V. The e⁄ciency of energy transfer (see
Eq. 1) is obtained experimentally from Eq. 4:
E  13 I
Io
4
where I and Io are the relative £uorescence yields of
the donor in the presence and absence of the accept-
or, respectively. The e⁄ciency of dipole^dipole
resonant energy transfer is heavily dependent
upon the vector distance between the donor^
acceptor pair; this distance must be less than 70 Aî
[18,19].
In this investigation, collisional quenching of Tb3
luminescence was evaluated by a modi¢ed Stern^
Volmer equation:
do
d
 1 kqdoQ 5
where do and d are the excited state lifetimes of the
probe in the absence and presence of quencher, re-
spectively; kq is the bimolecular quenching constant,
and [Q] is the concentration of quencher [26]. A plot
of do/d versus [Q] yields a slope equal to kqdo and a y-
intercept equal to one. The kq (in M31 s31) can be
used to ascertain the accessibility of Tb3 to cispla-
tin. The apparent Stern^Volmer quenching constant
(KSV) is the product of kq and do [26]. Quenching
interactions are generally described by a plot of Io/I
versus [Q], which yields a slope equivalent to KSV,
where Io is the intensity in the absence of quencher
and I is the intensity in the presence of quencher.
Collisional quenching processes are best described
by lifetime measurements [26].
The intensity of Tb3 luminescence has been ob-
served to decay exponentially after the withdrawal of
the excitation source [27]. The excited state lifetime
of Tb3 may be determined by the pulse-sampling
method [26]. The intensity of Tb3 at 543 nm was
measured as a function of the decay time. The loga-
rithm of the intensities were plotted against the delay
time; the photomultiplier delay interval was in-
creased from 0.05 ms to 1.50 ms, in increments of
0.05 ms. The slope of the line is equivalent to the
decay rate constant. The excited state lifetime of the
probe (d) is equal to the reciprocal of the decay rate
constant (U).
Binding equilibria are measured under conditions
in which there are detectable amounts of both free
and bound Tb3. The equilibrium binding constants
(vImax and Kd) were determined by using nonlinear
regression analysis on a modi¢ed Henri^Michaelis^
Menten equation [40]:
vI  vImaxTb
3
Kd  Tb3 6
where vI is proportional to the concentration of
cellular bound Tb3 at a particular Tb3 concentra-
tion, [Tb3]. The apparent maximum intensity
(vImax) for the Tb3^C13* complex is vI at satura-
tion, when all of the Tb3 binding sites are occupied
in the system. The apparent dissociation constant
(Kd) for the Tb3^C13* complex is the concentration
of Tb3 that gives a half-maximal response, i.e., 50%
of vImax ; the Kd re£ects the a⁄nity of C13* cells
for Tb3. The Eadie^Hofstee linear transformation
of the Henri^Michaelis^Menten equation was also
used to evaluate the equilibrium binding data; vI
was plotted against vI divided by its correspond-
ing Tb3 concentration. The intercept on the y-axis
is equal to vImax and the slope of the line is equiv-
alent to 3Kd. Although not as accurate as non-
linear regression analysis, this linear transformation
was employed to graphically visualize di¡erences
between the binding constants for the Tb3^C13*
complex in both the presence and absence of cispla-
tin.
The inhibition of the Tb3^C13* complex intensity
by cisplatin is indicative of the binding of cisplatin to
the C13* cells. The above titrations were done in the
presence and absence of 1.0 mM cisplatin. This high
concentration of cisplatin was employed to ensure a
signi¢cant reduction of Tb3 intensity. Cisplatin has
been shown to inhibit the intensity of cellular bound
Tb3 in a noncompetitive manner [11]. The apparent
inhibition constant (Ki) for the quenching of the
Tb3^C13* intensity by cisplatin was calculated by
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the equation:
vImax0  vImax
1 DDP
K i
7
where vImax0 and vImax are the maximum change in
intensity in the presence and absence of cisplatin,
respectively, and [DDP] is the cisplatin concentra-
tion. Note that Ki is equivalent to the Kd for the
Tb3^C13*^cisplatin complex.
The stoichiometry of binding (N) is the number of
high-a⁄nity Tb3 binding sites per cell, and was de-
termined by the following equation:
N  Tb
3
cell
 Tb
3total3Tb3free
cell 8
[Tb3]total is the total concentration of Tb3 incu-
bated with the cells in suspension, [Tb3]free is the
concentration of free Tb3 left in the ¢ltrate after
ultra¢ltration of the Tb3-labeled cells, and [cell] is
the concentration of cells in suspension. The value of
N is expressed as fmol/cell.
2.5. Data analysis
Data values are expressed as the mean þ standard
error of the mean (S.E.M.). Each value was the mean
of three to six data points; the exact number of ex-
periments are given in each ¢gure legend. Unpaired
Student’s t-tests were used to show the signi¢cance of
di¡erence between pairs of means. A one-way anal-
ysis of variance (ANOVA) was performed on the
quenching data to examine the e¡ect of cisplatin on
the lifetime and/or intensity of the Tb3^C13* com-
plex. A two-way ANOVA was used to evaluate the
relationship between the dose^e¡ect curves of cispla-
tin in the presence and absence of Tb3. The level of
signi¢cance is given each time a comparison is made;
the accepted level of signi¢cance was set at P6 0.05
for all statistical analyses.
3. Results
3.1. Luminescence characteristics of the Tb3+^C13*
complex
The equilibrium binding of Tb3 to C13* cells was
determined by a photometric titration procedure.
When increasing concentrations of Tb3 were added
to a C13* cell suspension, the luminescence intensity
of Tb3 increased in a hyperbolic fashion, gradually
tapering into a plateau at approximately 50 WM Tb3
(Fig. 1). Above 100 WM Tb3, the intensity began to
markedly increase as a function of the Tb3 concen-
tration. The fact that the luminescence became satu-
rated at a low Tb3 concentration is suggestive of the
binding of Tb3 to a high-a⁄nity site. It is clear,
from the Eadie^Hofstee plot shown in the inset of
Fig. 1, that the binding of Tb3 to C13* cells in-
volves at least two classes of binding sites. The Kd
for the binding of Tb3 to the high-a⁄nity site was
estimated to be 36.3 þ 5.2 WM and the Kd for the low
a⁄nity site was 101 þ 14 WM (P6 0.0001). Since the
intensity is proportional to the concentration of
probe, i.e., the number of Tb3 binding sites, the
theoretical maximum intensity at saturation for
each component suggests that the low-a⁄nity sites
(vImax = 233 þ 5) outnumber the high-a⁄nity sites
(vImax = 135 þ 7) by almost two to one (P6 0.0001).
The stoichiometry of binding of Tb3 to the high-
a⁄nity sites was determined to be 105 þ 2 fmol/cell
(n = 6). Further, the high-a⁄nity binding of Tb3 was
inhibited by Ca2 in a mixed-type manner (data not
shown); the Ki for Ca2 was determined to be 27
mM. This ¢nding suggests that the high-a⁄nity
Tb3 binding site is a Ca2 binding protein. The
binding of Tb3 to the di¡erent classes of binding
sites is dependent on the concentration of Tb3 in
solution. We chose Tb3 concentrations that were
either high enough to saturate the high-a⁄nity bind-
ing sites, or low enough to not bind an appreciable
amount of the low-a⁄nity binding sites. The high-
a⁄nity Tb3 binding site is designated the Tb3^
C13* complex.
The emission spectrum of the Tb3^C13* complex
was identical to that of free Tb3, displaying the
characteristic emission quartet at approximately
488, 543, 584 and 620 nm (Fig. 2). The intensity of
free, unbound, Tb3 is very weak in aqueous solu-
tion. However, when Tb3 binds to C13* cells and
forms a complex, its luminescence intensity is in-
creased 7-fold. The enhanced emission of cellular
bound Tb3 is sensitized by a dipole^dipole resonant
energy transfer mechanism. Aromatic amino acids
are directly excited by ultraviolet radiation
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(Vexc = 280 nm). Excitation energy is subsequently
transferred from the aromatic residues to the bound
probe. The formation of the Tb3^C13* complex
altered the excitation maxima in the 250 to 300 nm
region of the Tb3 spectrum (Fig. 3A). The value of
the 284/267 nm excitation intensity ratio for the
Tb3^C13* complex was 50% greater than that for
free Tb3 alone. An increase in this ratio con¢rms
that energy is being transferred from nearby aro-
matic residues to the bound Tb3 ion [21]. The ab-
sorbance of Tb3 is negligible at the excitation wave-
length employed here (280 nm), whereas, at this same
wavelength, the absorbance of the aromatic amino
acids is relatively strong. Therefore, the direct exci-
tation of Tb3 is poor, resulting in a lower value for
free Tb3 [28,29]. De Jersey et al. [30] have reported
that the 292 nm/276 nm excitation intensity ratio (R)
may be used to diagnose the aromatic chromophore
responsible for transferring excitation energy to
Tb3. Numerical R values have been associated
with the following aromatic residues: R6 0.2, union-
ized tyrosine; R = 0.5 to 1.0, tryptophan; Rs 1.8,
ionized tyrosine [30]. For the Tb3^C13* complex,
the value of R was equal to 0.8 which is indicative
of tryptophan as the energy donor (Fig. 3A). If phen-
ylalanine was the energy donor, then the excitation
spectrum of Tb3 would have had de¢nitive maxima
Fig. 2. Normalized luminescence emission spectra of Tb3 in
the presence and absence of C13* cells. Uncorrected emission
spectra of 10 WM Tb3 with cisplatin-resistant C13* human
ovarian cells at 2U104 cells ml31 in HBS solution (solid line),
and 10 WM Tb3 alone without cells (dotted line). Vexc = 280
nm. Each spectrum is the average of three scans.
Fig. 1. Equilibrium binding of Tb3 to C13* cells. vI is plotted as a function of the Tb3 concentration; vI was normalized to the
maximum intensity change at 100 WM Tb3. The C13* cells at 5U104 cells ml31 in HBS were titrated with Tb3 (2^1000 WM). The
intensity of the probe at 543 nm was measured after each aliquot (2^10 Wl) of either 3 mM Tb3 or 30 mM Tb3. Inset: Eadie^Hof-
stee linear transformation of the equilibrium binding data. vI is plotted against the quotient of vI divided by its corresponding Tb3
concentration. Mean þ S.E.M.; n = 9.
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at shorter wavelengths. The excitation di¡erence
spectrum of the probe, i.e., the excitation spectrum
of the Tb3^C13* complex minus that of the free
Tb3 ion, resembles the absorption spectrum of tryp-
tophan, having a maximum at 282 nm with a prom-
inent shoulder at 291 nm (Fig. 3B). Further, the cor-
rected emission maximum of the C13* cells
(Vmax = 333 nm) is consistent with that of tryptophan
residues in protein; this a⁄rms that tryptophan is
the energy donor [31,32].
To obtain a quantitative evaluation of the energy
transfer between Tb3 and tryptophan, as well as to
measure the average distance between the donor^ac-
ceptor pair, the e⁄ciency of energy transfer (E) and
the critical distance for 50% energy transfer (Ro)
were ¢rst ascertained. Partial suppression of the en-
ergy donors £uorescence emission is generally con-
sidered as the consequence of energy transfer. The
natural £uorescence emission of the C13* cells was
quenched by 24% in the presence of Tb3 (E = 0.2393
from Eq. 4). Fig. 4 shows the overlap between the
£uorescence emission spectrum of the C13* cells and
the absorption spectrum of the Tb3^EDTA com-
plex. Due to the extreme light scattering properties
of the cells and the weak absorptivity of the Tb3
ion, the absorption spectrum of the Tb3^EDTA
complex was used instead of the absorption spectrum
of cellular bound Tb3. From Eq. 3, J was calculated
to be 1.4U10319 cm3 M31. When the refractive index
(R) was taken as 1.36, K2 as 2/3 and Qo as 0.20, the
value of Ro was approx. 4.1 Aî (from Eq. 2). Thus,
according to Eq. 1, the distance between tryptophan
and Tb3 is calculated as 5 Aî . This value is a feasible
¢rst approximation. The literature has reported that,
in order for Tb3 luminescence to be sensitized via a
dipole^dipole energy transfer process, the probe must
be located within 5 to 10 Aî of the aromatic chromo-
phore [19,33].
Of the terms in Eq. 2, J and Qo are perhaps the
most susceptible to experimental error. As can be
Fig. 3. (A) Corrected luminescence excitation spectra of 100
WM Tb3 with (solid line) and without (dashed line) C13* cells
at 2U104 cells ml31 in HBS. The intensities of each spectra
were normalized to their respective intensity at 256 nm.
Vems = 543 nm. Each spectrum is the average of three scans. (B)
Excitation di¡erence spectrum between the Tb3^C13* complex
and free Tb3. At each wavelength, the intensity of 100 WM
Tb3 alone was subtracted from the corresponding intensity of
100 WM Tb3 with C13* cells at 2U104 cells ml31 in HBS.
These intensities were not normalized to their respective inten-
sity at 256 nm.
Fig. 4. Corrected £uorescence emission spectrum of C13* cells
(dotted line) and the long-wave ultraviolet absorption spectrum
of the Tb3^EDTA complex (solid line). The cell suspension
contained C13* cells at 2U104 cells ml31 in HBS. Vexc = 280
nm. The Tb3^EDTA was made at a 1:1 ratio, i.e., 0.6 mM
Tb3 and 0.6 mM EDTA, with 154 mM NaCl in 10 mM
Hepes, at pH 7.2. O352 nm = 0.22 M31 cm31. Each spectrum is
the average of three scans.
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seen from Eq. 3, the value of J is proportional to the
molar absorptivity of the absorbing chromophore. A
10-fold increase in the molar absorptivity would only
increase the value of Ro to 6 Aî and the value of r to
7.3 Aî . It was implied that the molar absorptivity of
the Tb3^EDTA complex in the region over which
the two spectra overlap closely approximates that of
the Tb3^C13* complex. However, the £uorescence
quantum yield for the C13* cells is not known. The
value of Qo for most proteins containing tryptophan
may vary from 0.001 to 0.46 [32]. Because the plasma
membrane of the C13* cells has a heterogeneous
population of protein, and because of the severe light
scattering properties of the cells, recourse was made
to use the Qo of free L-tryptophan (0.20) in aqueous
solution at 25‡C, pH 7.0 [32]. Had it been decided to
use the high value for Qo, the distance between tryp-
tophan and Tb3 would have only increased by 14%
to 5.7 Aî , well within the range for dipole^dipole
Fig. 5. Intensity of decay of the Tb3^C13* complex and Tb3
alone in HBS. The logarithm of the intensities of 100 WM Tb3
with C13* cells at 1U105 cells ml31 (b) and 1000 WM Tb3
alone (a) were plotted as function of the delay time. Vexc = 280
nm and Vems = 543 nm. Mean þ S.E.M; n = 3.
Fig. 6. Eadie^Hofstee analysis of the binding of Tb3 to C13* cells in the presence (b) and absence (a) of 1.0 mM cisplatin. The nor-
malized change in the Tb3^C13* intensity (vI) is plotted as a function of the quotient of vI divided by its corresponding Tb3 con-
centration. Inset: equilibrium binding of Tb3 to C13* cells in the presence (b) and absence (a) of cisplatin. vI is plotted as a func-
tion of the Tb3 concentration; vI was normalized to the maximum intensity change at 49 WM Tb3 in the absence of cisplatin. C13*
cells at 5U104 cells ml31 were incubated with either 0.0 or 1.0 mM cisplatin for 60 min at 37‡C. Throughout the titration, the con-
centration of free Tb3 was assumed to be equal to the total concentration of Tb3 added to the suspension, from 2 WM to 49 WM.
Mean þ S.E.M.; n = 6.
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resonant energy transfer. The refractive index of the
medium between Tb3 and tryptophan was taken as
1.36, which is an average between the refractive in-
dex of water (1.33) and that of speci¢c organic mol-
ecules (1.39) [34,35]. The value of K2, for an isotropic
donor and an isotropic acceptor, must lie between
the extremes 1/3 and 4/3 [29]; for this study, 2/3
was chosen as the value for K2, because any devia-
tion from this value would not seriously change the
value of Ro. The value of Ro would have changed
only by þ 12% when using 1/3 or 4/3 for K2. Fortu-
nately, since the evaluation of Ro depends on the
sixth root of the above parameters, minor uncertain-
ties in their absolute values are not important [29,36].
The luminescence lifetime of Tb3 has been shown
to be sensitive to changes in its immediate environ-
ment [27,37^39]. When Tb3 binds to protein, the
excited state lifetime of the probe undergoes a sig-
ni¢cant enhancement due to the removal of water
molecules from its immediate environment. The life-
time of the Tb3^C13* complex (0.70 þ 0.01 ms) was
two times greater than that of free Tb3 in bu¡er
(0.34 þ 0.01 ms) (Fig. 5). This value is very similar
to the lifetime obtained in other cell lines [36]. Fur-
ther, the decay of the Tb3^C13* intensity can be
adequately described by a single exponential equa-
tion, thus indicating that the probe resides in a ho-
mogeneous environment. The lifetime of free Tb3
in HBS was about 20% less than what we found
for pure water (0.42 þ 0.01 ms); the Hepes in the
bu¡er solution can interfere with Tb3 luminescence
[25].
3.2. Quenching of terbium luminescence by cisplatin
The quenching of Tb3 luminescence by cisplatin
was used to describe the interaction of cisplatin with
the plasma membrane of C13* cells. In the presence
of cisplatin, the intensity of the Tb3^C13* complex
followed equilibrium binding kinetics as a function
of the Tb3 concentration (Inset of Fig. 6). The vImax
for the Tb3^C13* complex decreased by 49% in the
presence of cisplatin, compared to the vImax for the
Tb3^C13* complex without cisplatin (P6 0.0001).
However, the Kd for the Tb3^C13* complex did
not appreciably change in the presence of cisplatin
(Ps 0.08), as indicated by parallel slopes in Fig. 6.
Therefore, cisplatin reduced the Tb3^C13* intensity
without a¡ecting the a⁄nity of the C13* cells for
Tb3. This is characteristic of noncompetitive inhi-
bition. The degree of quenching of the Tb3^C13*
intensity depends upon the concentration of cisplatin
and the a⁄nity of cisplatin for the Tb3^C13* com-
plex [40]. The inhibition constant (Ki) for the
quenching of the Tb3^C13* intensity by cisplatin
is equivalent to the Kd for the Tb3^C13*^cisplatin
complex and was calculated from Eq. 7 as 1042 WM.
This indicates that the a⁄nity of the C13* cells for
cisplatin is much less than the a⁄nity of the C13*
cells for Tb3. The stoichiometry of binding of Tb3
to the C13* cells increased slightly (by 12%) to
118 þ 5 fmol/cell (n = 6) in the presence of cisplatin
(P6 0.03). Therefore, the quenching of the Tb3^
C13* intensity by cisplatin is due to a mechanism
Fig. 7. Stern^Volmer quenching analysis of Tb3 luminescence
by cisplatin. The lifetime (A) and intensity (B) of both free
Tb3 (a) and the Tb3^C13* complex (b) were measured in the
presence of various concentrations of cisplatin. Before each de-
termination, 1000 WM Tb3 without cells, or 100 WM Tb3 with
C13* cells at 1U105 cells ml31, were permitted to equilibrate in
the presence of either 0.0, 0.5, 1.0, 1.5 or 2.0 mM cisplatin for
60 min at 37‡C in HBS. Mean þ S.E.M.; n = 3.
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that does not require the displacement of Tb3 from
its high-a⁄nity binding site.
Stern^Volmer quenching analysis was employed to
ascertain the accessibility of the Tb3 binding site to
cisplatin and to determine the nature of the quench-
ing process. Fig. 7A reveals that the average free
Tb3 ion encounters many cisplatin molecules during
its lifetime, from Eq. 5 kq = 1.1U106 M31 s31 for free
Tb3. The decrease in the lifetime of Tb3 occurs
because the collision between cisplatin and Tb3 is
an additional rate process [26]. However, for the
Tb3^C13* complex, kq = 1.2U105 M31 s31, which
is 9-fold less than the value for free Tb3. The bind-
ing of Tb3 to the C13* cell decreased the rate of
bimolecular quenching with cisplatin. This indicates
that the Tb3 binding site is not readily accessible to
cisplatin; the bound Tb3 ion must be buried within
the plasma membrane. According to Stern^Volmer
quenching analysis for static quenching, do/d = 1
[26]. The ratio do/d for the Tb3^C13* complex did
not appreciably change between 0.5 and 2.0 mM cis-
platin, averaging 1.14 þ 0.02 (Ps 0.2). Consequently,
cisplatin primarily inhibits the lifetime of bound
Tb3 via a static quenching process. The binding of
cisplatin to the Tb3^C13* complex produces a non-
luminescent structure, i.e, the Tb3^C13*^cisplatin
complex; the observed luminescence is from the un-
perturbed Tb3^C13* complex.
Fig. 7A,B also illustrate an important concept of
dynamic, or collisional, quenching. Theoretically,
collisional quenching involves an equivalent decrease
in luminescence intensity and lifetime; i.e., Io/I = do/d
[26]. The KSV for free Tb3 (460 þ 55 M31) from the
intensity measurements in Fig. 7B was similar to the
KSV for free Tb3 (370 þ 10 M31) from the lifetime
measurements in Fig. 7A (Ps 0.1). The decrease in
Tb3 intensity occurs because the rate of quenching
by cisplatin depopulates the excited state of the
probe without luminescence emission [26]. The
quenching of free Tb3 luminescence by cisplatin is
by a dynamic, collisional process. However, for the
Tb3^C13* complex, the KSV in Fig. 7B (750 þ 50
M31) was nine times greater than that in Fig. 7A
(80 þ 5 M31) (P6 0.001). A decrease in the Tb3^
C13* intensity did not result in an equivalent de-
crease in the Tb3^C13* lifetime, i.e., Io/Ig do/d.
This con¢rms that the quenching of Tb3^C13* lu-
minescence by cisplatin occurs by a static process;
KSV is the apparent association constant for the for-
mation of the Tb3^C13*^cisplatin complex. The
value of KSV from Fig. 7B (750 þ 50 M31) is some-
what similar to that obtained from Fig. 4 and Eq. 7
(960 M31 ; the reciprocal of Ki is the apparent asso-
ciation constant for the Tb3^C13*^cisplatin com-
plex). The linearity of the Stern^Volmer plots is in-
dicative of a single class of high-a⁄nity Tb3 binding
sites on the surface of the C13* cell.
The observed KSV from Fig. 7B, i.e., the quenching
of the Tb3^C13* intensity by cisplatin, was much
greater than what could be accounted for if only an
electron exchange interaction had occurred. An addi-
tional mechanism must also be involved in the
quenching of the Tb3^C13* intensity by cisplatin.
The absorption of cisplatin is absent in the visible
region of the spectrum. Consequently, the spectral
overlap between the emission bands of Tb3 and
the absorption spectrum of cisplatin is negligible in
the 470^640 nm range, i.e., J = 0. Therefore, cisplatin
cannot quench the intensity of Tb3 via a through-
space dipolar interaction. A prerequisite for dipole^
dipole resonant energy transfer is that there must be
su⁄cient spectral overlap between the donor emis-
sion and the acceptor absorption. As shown in Fig.
8, the spectral overlap between the emission spec-
trum of tryptophan and the absorption spectrum of
Fig. 8. Corrected £uorescence emission spectrum of C13* cells
(dotted line) and ultraviolet absorption spectrum of cisplatin
(solid line) in HBS. The cell suspension contained C13* cells at
2U104 cells ml31 in HBS. Vexc = 280 nm. The ultraviolet ab-
sorption spectrum of 1.0 mM cisplatin in HBS was recorded at
room temperature. O301 nm = 111 M31 cm31. Each spectrum was
the average of three scans.
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cisplatin was substantial enough to disrupt the sensi-
tization of Tb3 luminescence by tryptophan. The
spectral overlap integral for tryptophan and cisplatin
(J = 2.7U10317 cm3 M31) is approximately 200 times
greater than the spectral overlap integral for trypto-
phan and Tb3, due to the greater molar absorptivity
of cisplatin in the 310^390 nm region (Fig. 4 vs. Fig.
8). Accordingly, the e⁄ciency of energy transfer
(E = 0.47) and the critical distance for 50% energy
transfer (Ro = 9.8 Aî ) were calculated and were used
to measure the distance between tryptophan and cis-
platin; in this case, r = 10 Aî .
4. Discussion
In this report, we described the binding of cisplatin
and Tb3 to cisplatin-resistant C13* human ovarian
cancer cells. Like most intact cell systems, two classes
of Tb3 binding sites were detected on the surface of
C13* cells [20,21]. The low-a⁄nity Tb3 binding sites
were di⁄cult to study and not examined. The high-
a⁄nity Tb3 sites are less abundant than the low-
a⁄nity sites, having a Kd in the micromolar range.
In agreement with the literature, Ca2 was found to
compete with Tb3 for the high-a⁄nity binding sites,
having a Ki in the millimolar range [20,21]. The af-
¢nity of the C13* cells for Ca2 is much less than
that for Tb3 because of the more electropositive
character of Tb3. The enhancement of Tb3 lumi-
nescence was indicative of the membrane binding of
Tb3 ; the intensity of Tb3 is sensitized by radiation-
less energy transfer from aromatic amino acids in the
vicinity of the bound probe. Examination of the
Tb3 excitation spectrum revealed tryptophan as
the energy donor in the Tb3^C13* complex [21].
Tryptophan has been shown to transfer excitation
energy to Tb3 in many protein and biological mem-
brane systems [19^21,29,30,34,35,41]. Unlike tyrosine
and phenylalanine, the £uorescence emission of tryp-
tophan is sensitive to its microenvironment. The
emission maximum of tryptophan is around 350
nm in an aqueous environment; but, when trypto-
phan is buried within the nonpolar regions of the
protein and shielded from the aqueous environment,
its emission maximum is blue-shifted toward 330 nm
[26,32,42]. An accurate description of the structures
at the Tb3 binding site is necessary to ascertain the
molecular events involved in the binding and trans-
port of cisplatin.
Fo«rster’s theory of dipole^dipole energy transfer
has been veri¢ed experimentally and used to measure
the distance between tryptophan donors and Tb3
acceptors in a variety of proteins [29,34,35,41]. The
tryptophan amino and the Tb3 binding site are spa-
tially close on the surface of the plasma membrane.
Further, the excitation of Tb3 in the Tb3^C13*
complex does not require a powerful energy source
(such as a laser) nor a relatively high Tb3 concen-
tration (s 1032 M). The degree of enhancement of
Tb3 luminescence becomes negligible when the dis-
tance between the donor^acceptor pair exceeds 10 Aî
[19,30]. In the Tb3^C13* complex, the estimated 5
Aî separation between tryptophan and Tb3 falls well
below this value.
Because Tb3 is sequestered away from deactivat-
ing water molecules, the lifetime of Tb3 lumines-
cence undergoes a signi¢cant enhancement when
Tb3 binds to the C13* cells. The dominant mode
of radiationless deactivation of the excited state of
Tb3 is by energy transfer to the vibrational levels of
the water molecules in its hydration sphere
[27,37,38]. This loss of energy is proportional to the
number of high-frequency hydrogen stretch vibra-
tions (i.e., O^H bonds) in the local environment.
The decay rate constant for Tb3^protein complexes
has been shown to vary linearly with the mole frac-
tion of H2O in H2O^D2O mixtures [38]. The lumi-
nescence decay constant of Tb3 is an established
and reliable measure of the number of water mole-
cules in its primary coordination sphere [37,38]. In an
aqueous solution, there are nine water molecules in
the ¢rst coordination sphere of Tb3. Perhaps, the
formation of the Tb3^C13* complex stripped away
approximately four or ¢ve water molecules from the
hydration sphere of the probe, thus doubling the life-
time of Tb3.
The inhibition of Tb3 intensity by cisplatin has
been demonstrated by Canada [11], and later con-
¢rmed by Simpkins et al. [43]. The bimolecular
quenching constant reported here for free Tb3 and
cisplatin lies within the range calculated for energy
transfer in the rapid-di¡usion limit [44,45]. The colli-
sional quenching of the excited state lifetime of Tb3
occurs via an electron exchange interaction with cis-
platin [45]. In the rapid-di¡usion limit, the average
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separation between Tb3 and cisplatin is less than
the distance di¡used by Tb3 during its long lived
excited state. At the instant of excitation, Tb3 and
cisplatin are brought into close proximity by di¡u-
sion. A through-space electron exchange interaction
is strongly dependent on the distance of closet ap-
proach between the donor^acceptor pair [44]. While
the probe is still in its excited state, the electron
cloud of free, unbound, Tb3 can overlap the elec-
tron cloud of cisplatin. In contrast, the collisional
quenching of the probe is attenuated in the Tb3^
C13* complex. Cisplatin inhibited the intensity of the
Tb3^C13* complex in a noncompetitive fashion.
The net e¡ect of cisplatin was to make it seem as if
less Tb3 binding sites were present on the cells [40].
However, the number of Tb3 binding sites per C13*
cell was not reduced in the presence of cisplatin.
Also, the a⁄nity of Tb3 for the C13* cells was
not a¡ected by cisplatin; the Kd for the Tb3^C13*
complex was similar to that reported in other cell
lines [21,46]. Cisplatin and Tb3 bind to C13* cells
in a reversible, random and independent manner.
The Tb3 binding site is buried beneath the surface
of the plasma membrane, and this limits the accessi-
bility of the bound probe to the aqueous environ-
ment and cisplatin. However, the intensity of the
Tb3^C13* complex is e¡ectively quenched by cispla-
tin via a static quenching process. Such quenching is
believed to be due to the disruption of the energy
transfer between tryptophan and Tb3 by cisplatin.
This is based on the following facts: (1) the UV
absorbance of cisplatin is signi¢cantly greater than
the UV absorbance of Tb3 ; (2) the spectral overlap
between the emission spectrum of bound Tb3 and
the absorbance of cisplatin is negligible; (3) the spec-
tral overlap between the emission spectrum of tryp-
tophan and the absorption spectrum of cisplatin is
considerably greater than the spectral overlap be-
tween the emission spectrum of tryptophan and the
absorption spectrum of Tb3 ; and (4) cisplatin can
quench the intrinsic £uorescence emission of the
C13* cells alone. Hence, the quenching of the native
cell £uorescence by cisplatin was assumed to be by a
Fo«rster-type dipole^dipole resonant energy transfer
mechanism, which permits the measurement of the
distance between tryptophan and cisplatin (10 Aî ).
It is important to recognize that the spectral over-
lap between the donor^acceptor pair does not neces-
sarily imply a dipole^dipole energy transfer mecha-
nism. At short donor^acceptor distances, energy
transfer involving tryptophan residues as the energy
donor has been proposed to arise from the triplet
state of the indole ring [28]. The rules for long-range
triplet^singlet energy transfer, via a dipole^dipole in-
teraction, have the same constants and power-de-
pendence as that for singlet^singlet energy transfer
[47,48]. However, energy transfer by an exchange
interaction becomes dominant when the donor and
acceptor pair are separated by a distance less than
11 Aî [44,45]. The excited state lifetime of the energy
donor and the concentration of the energy acceptor
determines the e⁄ciency of energy transfer via an
electron exchange interaction [45]. The exact mecha-
nism by which energy is transferred from tryptophan
to Tb3, and from tryptophan to cisplatin, is not
fully understood. In any case, the rate of energy
transfer between Tb3 and cisplatin is relatively small
when compared to the rate of energy transfer be-
tween tryptophan and cisplatin. Previously, we pre-
sumed that cisplatin directly quenched the intensity
of the Tb3^C13* complex by an electron exchange
process [11,36]. It is now believed that cisplatin per-
turbs the £ow of excitation energy from tryptophan
to Tb3, thereby indirectly quenching the intensity of
the bound probe. The distance between cisplatin and
Tb3 in the Tb3^C13*^cisplatin complex is greater
than 5 Aî , but less than 15 Aî . Therefore, the cisplatin
and Tb3 binding sites are close enough to in£uence
the electrostatic forces in their microenvironments.
A unique feature of the Tb3 binding site is the
integration of two mutually exclusive properties: ion
binding and hydrophobicity. Cation^Z interactions
are important in the binding of cationic ligands to
aromatic (hydrophobic) binding sites [49]. The quad-
rupole moment of the indole ring structure of tryp-
tophan provides a highly negative electrostatic po-
tential which establishes a very strong noncovalent
binding force between the Z face of indole and
Tb3. Cation^Z interactions may also be involved
in the membrane binding of cisplatin. Removal of
the two labile chlorine atoms of cisplatin may result
in a positively charged species that is capable of
binding tryptophan [50,51].
The importance of cisplatin in the treatment of
ovarian cancer is unquestioned. However, the devel-
opment of cisplatin resistance is a serious drawback
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to cisplatin chemotherapy and is the main factor af-
fecting treatment outcome [3]. The defective accumu-
lation of cisplatin has been demonstrated in many
cisplatin-resistant human ovarian cancer cells includ-
ing the C13* cell line. Reduction of cisplatin accu-
mulation is suggested to be due to impaired drug
transport processes. The cellular accumulation and
cytotoxicity of cisplatin has been shown to be en-
hanced in the presence of Tb3 in human breast
and ovarian cancer cells [12,13,15,16]. Studies focus-
ing on the physiological nature of the binding of
Tb3 and cisplatin to the cancer cell membrane are
currently under investigation and are necessary be-
cause of the potential role that this binding may play
in understanding the reversal of cisplatin accumula-
tion defects.
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